Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Relapsed and refractory Diffuse Large B Cell Lymphoma (rrDLBCL) presents a significant challenge in hematology-oncology, with approximately 30-40% of DLBCL patients experiencing relapse or resistance to treatment. This underscores the urgent need to better understand the molecular mechanisms governing therapeutic resistance. Signal Transducer and Activator of Transcription 6 (STAT6) has been previously identified as a gene with recurrent D419 gain-of-function mutations in rrDLCBL. When STAT6D419mutations are present in DLBCL tumour cells, we have demonstrated that transcription of the chemokine CCL17 (aka TARC) is increased, and tumours have increased infiltration of CD4+ T cells. However, the significance of increased T cell infiltration had not been determined. In the present study, we developed a mouse model of STAT6D419Nmutant DLBCL, that recapitulates the critical features of human STAT6D419mutant DLBCL, including increased expression of phospho-STAT6, increased CD4+ T cell invasion, and resistance to doxorubicin treatment. With this model, we found CD4+ T cells in STAT6D419Ntumours have higher expression of the receptor for CCL17, CCR4. Usingex vivofunctional assays we demonstrate that STAT6D419Ntumour cells are directly chemoattractive to CCR4+ CD4+ T cells, and when CCR4 is inhibited using a small molecule antagonist, CD4+ T cells in STAT6D419Ntumours are reduced and STAT6D419Ntumours regain therapeutic sensitivity to doxorubicin. Using PhenoCycler imaging of human rrDLBCL samples, we find that STAT6D419tumours indeed have increased expression of phospho-STAT6+ and increased cellular interactions between phospho-STAT6+ tumour cells and CD4+/ CCR4+ CD4+ T cells. Thus, our data identify CCR4 as an attractive therapeutic target in STAT6D419mutant rrDLBCL.
Relapsed and refractory Diffuse Large B Cell Lymphoma (rrDLBCL) presents a significant challenge in hematology-oncology, with approximately 30-40% of DLBCL patients experiencing relapse or resistance to treatment. This underscores the urgent need to better understand the molecular mechanisms governing therapeutic resistance. Signal Transducer and Activator of Transcription 6 (STAT6) has been previously identified as a gene with recurrent D419 gain-of-function mutations in rrDLCBL. When STAT6D419mutations are present in DLBCL tumour cells, we have demonstrated that transcription of the chemokine CCL17 (aka TARC) is increased, and tumours have increased infiltration of CD4+ T cells. However, the significance of increased T cell infiltration had not been determined. In the present study, we developed a mouse model of STAT6D419Nmutant DLBCL, that recapitulates the critical features of human STAT6D419mutant DLBCL, including increased expression of phospho-STAT6, increased CD4+ T cell invasion, and resistance to doxorubicin treatment. With this model, we found CD4+ T cells in STAT6D419Ntumours have higher expression of the receptor for CCL17, CCR4. Usingex vivofunctional assays we demonstrate that STAT6D419Ntumour cells are directly chemoattractive to CCR4+ CD4+ T cells, and when CCR4 is inhibited using a small molecule antagonist, CD4+ T cells in STAT6D419Ntumours are reduced and STAT6D419Ntumours regain therapeutic sensitivity to doxorubicin. Using PhenoCycler imaging of human rrDLBCL samples, we find that STAT6D419tumours indeed have increased expression of phospho-STAT6+ and increased cellular interactions between phospho-STAT6+ tumour cells and CD4+/ CCR4+ CD4+ T cells. Thus, our data identify CCR4 as an attractive therapeutic target in STAT6D419mutant rrDLBCL.
Background Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by progressive joint damage and functional limitations, often accompanied by comorbidities. While the impact of immune cells on the development of RA is recognized, the precise causal relationships with various immunophenotypes are yet to be fully understood. Methods We performed a comprehensive two-sample Mendelian randomization (MR) study to explore the associations between immunophenotypes and RA. Utilizing publicly available genetic datasets, we examined causal links involving 731 immune cell traits, categorized into four groups: relative cell counts (RC), median fluorescence intensities (MFI), morphological parameters (MP), and absolute cell counts (AC). Extensive sensitivity analyses were carried out to validate the robustness of our results. These analyses aimed to assess heterogeneity and investigate the potential influence of horizontal pleiotropy. Results After applying FDR correction, two specific immunophenotypes were found to be associated with RA: CD33dim HLA-DR + CD11b+ %CD33dim HLA-DR + and CD33dimHLA-DR + CD11b-%CD33dimHLA-DR+. The odds ratios (ORs) for RA risk forthese immunophenotypes, calculated using the inverse variance weighting(IVW) method, were 0.970 (95% CI = 0.955–0.985, P = 1.09×10− 4, PFDR = 0.058) and 1.027 (95% CI = 1.011–1.042, P = 5.05×10− 4, PFDR = 0.074), respectively. In contrast, without FDR correction, six additional immunophenotypes showed significant associations with RA: CD14 on CD33dim HLA-DR + CD11b+, CD16 on CD14 + CD16 + monocytes, CD11b on basophils, CD3 on TD CD4+, PDL-1 on CD14- CD16 + monocytes, and CD4 on HLA-DR + CD4+. Of these, the first two were linked to increased RA risk, while the latter four exhibited protective characteristics. Conclusions This study highlights a strong genetic link between immune cell profiles and RA, illuminating potential targets for innovative therapeutic strategies.
ObjectivesInflammatory cytokines (ICs) play an important role in erectile dysfunction (ED). Previous studies have demonstrated that most ED patients have high levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8). The causality between 41 ICs and ED is investigated using the Mendelian randomization (MR) approach.MethodsSingle nucleotide polymorphisms (SNPs) exposure data of 41 ICs came from a genome-wide association study (GWAS) of 8293 subjects. At the same time, the FINNGEN R9 database provided the ED outcome data containing 2205 ED patients and 164104 controls. MR-Egger (ME), inverse variance weighting (IVW), and weighted median (WM) were applied to conduct the MR study and IVW was taken as the main criterion.ResultsFrom a genetic perspective, the increase of interferon-inducible protein-10 (IP-10) level significantly increased the risk of ED (P=0.043, odds ratio (OR)=1.269, 95% confidence interval (95%CI): 1.007-1.600), while the increase of interleukin-1 receptor antagonist (IL-1RA) markedly decreased the risk of ED (P=0.037, OR=0.768, 95%CI: 0.600-0.984). Meanwhile, IP-10 (p=0.099) and IL-1RA (p=0.135) failed to demonstrate causality in reverse MR analysis.ConclusionsChanges in ICs levels will significantly affect the risk of ED, especially IP-10 as a risk component for ED and IL-1RA as a protective component for ED. In the future, we can achieve targeted treatment and prevention of ED by intervening with specific inflammatory factors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.